论文部分内容阅读
目的:评价左氧氟沙星用于耐多药肺结核治疗的有效性和安全性。方法:选取2012年4月-2014年4月于我院就诊的耐多药肺结核患者94例,随机分为氧氟沙星组和左氧氟沙星组。观察两组痰菌阴转率、病灶吸收率及不良反应情况。结果:左氧氟沙星组痰菌转阴率为95.7%,较氧氟沙星组80.9%显著升高,差异有统计学意义(P<0.05);左氧氟沙星组的吸收率为93.6%,也较氧氟沙星组74.5%显著升高,差异有统计学意义(P<0.05);左氧氟沙星组的治疗总有效率为93.6%,较氧氟沙星组72.3%显著升高,差异具有统计学意义(P<0.05);氧氟沙星组不良反应发生率为29.8%,左氧氟沙星组不良反应发生率为12.8%,差异具有统计学意义(P<0.05)。结论:左氧氟沙星对于耐多药肺结核的疗效显著,且能减少不良反应的发生。
Objective: To evaluate the efficacy and safety of levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis. Methods: A total of 94 MDR-TB patients treated in our hospital from April 2012 to April 2014 were randomly divided into ofloxacin group and levofloxacin group. Two groups of sputum negative conversion rate, absorption rate and adverse reactions were observed. Results: The leaching rate of sputum bacterium in levofloxacin group was 95.7%, which was significantly higher than that of ofloxacin group 80.9% (P <0.05). The absorption rate of levofloxacin group was 93.6% 74.5% in star group increased significantly (P <0.05), the total effective rate of levofloxacin group was 93.6%, which was significantly higher than that of ofloxacin group (72.3%), the difference was statistically significant (P < 0.05). The incidence of adverse reactions in ofloxacin group was 29.8%, and the incidence of adverse reactions in levofloxacin group was 12.8%. The difference was statistically significant (P <0.05). Conclusion: Levofloxacin has significant therapeutic effect on multidrug-resistant pulmonary tuberculosis and can reduce the incidence of adverse reactions.